Trials / Recruiting
RecruitingNCT04792801
PET TDM FDG-Choline as a Decision-making Tool for Routine Care on the Liver Transplant List for HCC
Evaluation of PET TDM FDG-Choline as a Decision-making Tool for Routine Care on Inclusion on the Liver Transplant List for Hepatocellular Carcinoma
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 100 (estimated)
- Sponsor
- University Hospital, Lille · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
HCC is the most common malignant liver tumor for which liver transplantation is one of the pivotal curative treatments. The best possible selection of patients who are candidates for transplantation is essential in the current context of a shortage of transplants. Performing a PET CT scan is not currently recommended in the pre-liver transplant workup for HCC. However, PET CT using in a complementary manner the FDG and Choline tracers appears promising in the management of HCC in view of its wide use in oncology and its major diagnostic and prognostic contribution compared to conventional imaging. In order to address this issue, a prospective cohort study including patients from the University Hospital of Rouen and Lille with hepatocellular carcinoma meeting the criteria for indication of liver transplantation validated in SPC will be set up, the main objective of which will be to assess the decision-making contribution of PET TDM FDG and Choline in addition to conventional imaging in the pre-transplant assessment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | PET TDM FDG-Choline | Performing an FDG TDM PET and a Choline TDM PET at two different times |
Timeline
- Start date
- 2021-06-22
- Primary completion
- 2028-06-01
- Completion
- 2028-06-01
- First posted
- 2021-03-11
- Last updated
- 2022-03-15
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT04792801. Inclusion in this directory is not an endorsement.